Home
| Databases
| WorldLII
| Search
| Feedback
Generic Top Level Domain Name (gTLD) Decisions |
G.D. Searle & Co. v. J. Roller
Management
Claim Number: FA0209000126643
PARTIES
Complainant
is G.D. Searle & Co., Skokie, IL
(“Complainant”) represented by Paul D.
McGrady, of Ladas & Parry. Respondent is J. Roller Management, Las Vegas, NV (“Respondent”).
REGISTRAR AND DISPUTED DOMAIN NAME
The
domain name at issue is <buy-celebrex-prescriptions-online.com>,
registered with Bulkregister.
PANEL
The
undersigned certifies that he has acted independently and impartially and to
the best of his knowledge has no known conflict in
serving as Panelist in this
proceeding.
Tyrus
R. Atkinson, Jr., as Panelist.
PROCEDURAL HISTORY
Complainant
submitted a Complaint to the National Arbitration Forum (the “Forum”)
electronically on September 27, 2002; the Forum
received a hard copy of the
Complaint on September 30, 2002.
On
September 30, 2002, Bulkregister confirmed by e-mail to the Forum that the
domain name <buy-celebrex-prescriptions-online.com>
is registered with Bulkregister and that Respondent is the current registrant
of the name. Bulkregister has verified
that Respondent is bound by the Bulkregister registration agreement and has
thereby agreed to resolve domain-name
disputes brought by third parties in
accordance with ICANN’s Uniform Domain Name Dispute Resolution Policy (the
“Policy”).
On
October 1, 2002, a Notification of Complaint and Commencement of Administrative
Proceeding (the “Commencement Notification”), setting
a deadline of October 21,
2002 by which Respondent could file a Response to the Complaint, was
transmitted to Respondent via e-mail,
post and fax, to all entities and persons
listed on Respondent’s registration as technical, administrative and billing
contacts,
and to postmaster@buy-celebrex-prescriptions-online.com by e-mail.
Having
received no Response from Respondent, using the same contact details and
methods as were used for the Commencement Notification,
the Forum transmitted
to the parties a Notification of Respondent Default.
On
November 11, 2002, pursuant to Complainant’s request to have the dispute
decided by a single-member Panel, the Forum appointed
Tyrus R. Atkinson, Jr.,
as Panelist.
Having
reviewed the communications records, the Administrative Panel (the “Panel”)
finds that the Forum has discharged its responsibility
under Paragraph 2(a) of
the Rules for Uniform Domain Name Dispute Resolution Policy (the “Rules”) “to
employ reasonably available
means calculated to achieve actual notice to
Respondent.” Therefore, the Panel may
issue its decision based on the documents submitted and in accordance with the
ICANN Policy, ICANN Rules,
the Forum’s Supplemental Rules and any rules and
principles of law that the Panel deems applicable, without the benefit of any
Response
from Respondent.
RELIEF SOUGHT
Complainant
requests that the domain name be transferred from Respondent to Complainant.
PARTIES’ CONTENTIONS
A.
Complainant
The
<buy-celebrex-prescriptions-online.com>
domain name is confusingly similar to Complainant's CELEBREX mark.
Respondent
has no rights or legitimate interests in the disputed domain name.
Respondent registered and used the
disputed domain name in bad faith.
B.
Respondent
Respondent
failed to submit a Response.
FINDINGS
Complainant has registered its CELEBREX
mark in 112 countries around the world, including the United States. Complainant’s mark is registered on the
Principal Register of the United States Patent and Trademark Office as
Registration Number
2,321,622.
Complainant’s mark represents “pharmaceutical products in the nature of
anti-inflammatory analgesics.”
Complainant has promoted its CELEBREX mark on a global scale. Due to its extensive marketing and
advertising promoting the CELEBREX mark, the mark has earned worldwide
notoriety. The New York Times
referred to Complainant’s CELEBREX product as a “blockbuster arthritis drug,”
and Forbes referred to CELEBREX as the “sales crown jewel in
[Complainant’s] new portfolio.”
Respondent registered the disputed domain
name on March 19, 2002. The disputed
domain name currently does not display a website. Complainant’s investigation revealed that Respondent had been
using the <buy-celebrex-prescriptions-online.com>
domain name in connection with a software entity named “Red Hair” to solicit software
orders. Respondent does not have a
license to use the CELEBREX mark.
DISCUSSION
Paragraph 15(a) of the Rules instructs this Panel to
“decide a complaint on the basis of the statements and documents submitted in
accordance with the Policy, these Rules and any rules and principles of law
that it deems applicable.”
In view
of Respondent's failure to submit a Response, the Panel shall decide this
administrative proceeding on the basis of the Complainant's
undisputed
representations pursuant to paragraphs 5(e), 14(a) and 15(a) of the Rules and
draw such inferences it considers appropriate
pursuant to paragraph 14(b) of
the Rules.
Paragraph
4(a) of the Policy requires that the Complainant must prove each of the
following three elements to obtain an order that
a domain name should be
cancelled or transferred:
(1) the domain name registered by Respondent
is identical or confusingly similar to a trademark or service mark in which
Complainant has
rights; and
(2)
Respondent has no rights or legitimate interests in respect of the domain name;
and
(3)
the domain name has been registered and is being used in bad faith.
Identical and/or Confusingly Similar
Complainant has established that it has
rights in the CELEBREX mark through registration of the mark internationally
and with the
United States Patent and Trademark Office.
Respondent’s <buy-celebrex-prescriptions-online.com> domain name is confusingly similar to Complainant’s CELEBREX mark because
it merely adds the descriptive terms “buy,” “prescriptions,”
and “online.” The use of these words creates the phrase
“Buy Celebrex prescriptions online,” and therefore conveys to the Internet user
that CELEBREX
brand drugs are available at this particular domain name. As a result, CELEBREX is still the dominant
part of the domain name and the additional words do not give the domain name
any distinctive
qualities capable of overcoming a claim of confusing
similarity. See Sony Kabushiki Kaisha v. Inja, Kil,
D2000-1409 (WIPO Dec. 9, 2000) (finding that “[n]either the addition of an
ordinary descriptive word…nor the suffix ‘.com’ detract
from the overall
impression of the dominant part of the name in each case, namely the trademark
SONY” and thus Policy ¶ 4(a)(i) is
satisfied); see also Perot Sys. Corp. v. Perot.net, FA 95312
(Nat. Arb. Forum Aug. 29, 2000) (finding that, given the similarity of
Complainant’s marks with the domain name, consumers
will presume the domain
name is affiliated with Complainant; Respondent is attracting Internet users to
a website, for commercial
gain, by creating a likelihood of confusion with Complainant’s mark as to the source,
sponsorship, or endorsement of Respondent’s website).
The Panel finds that Policy ¶ 4(a)(i) has
been satisfied.
Rights or Legitimate Interests
Respondent has failed to respond,
therefore it is assumed that Respondent lacks rights and legitimate interests
in the disputed domain
name. When
Complainant asserts a prima facie case against Respondent, the burden of
proof shifts to Respondent to show that it has rights or legitimate interests
pursuant to
Policy ¶ 4(a)(ii). See
Do The Hustle, LLC v. Tropic Web, D2000-0624 (WIPO Aug. 21, 2000) (finding
that once Complainant asserts that Respondent has no rights or legitimate
interests in
respect of the domain, the burden shifts to Respondent to provide
credible evidence that substantiates its claim of rights and legitimate
interests in the domain name); see also Parfums Christian Dior v. QTR Corp., D2000-0023 (WIPO Mar. 9, 2000)
(finding that by not submitting a Response, Respondent has failed to invoke any
circumstance which
could demonstrate any rights or legitimate interests in the
domain name).
Furthermore, because Respondent has not
submitted a Response, it is appropriate for the Panel to accept all reasonable
allegations
and inferences in the Complaint as true. See Vertical
Solutions Mgmt., Inc. v. webnet-marketing, inc., FA 95095 (Nat. Arb. Forum
July 31, 2000) (failure to respond allows all reasonable inferences of fact in
the allegations of Complainant
to be deemed true); see also Charles Jourdan Holding AG v. AAIM,
D2000-0403 (WIPO June 27, 2000) (finding it appropriate for the Panel to draw
adverse inferences from Respondent’s failure to reply
to the Complaint).
Respondent uses the disputed domain name
in order to attract Internet users to its website, where it solicits orders for
a software
company that has no connection with Complainant. Respondent is therefore using Complainant’s
mark in order to attract Internet users looking for Complainant to Respondent’s
website. This type of use is not in
connection with a bona fide offering of goods or services pursuant to Policy ¶
4(c)(i), or a legitimate
noncommercial or fair use pursuant to Policy ¶
4(c)(iii). See Big Dog Holdings, Inc. v. Day, FA 93554
(Nat. Arb. Forum Mar. 9, 2000) (finding no legitimate use when Respondent was
diverting consumers to its own website by
using Complainant’s trademarks); see
also MSNBC Cable, LLC v. Tysys.com,
D2000-1204 (WIPO Dec. 8, 2000) (finding no rights or legitimate interests in
the famous MSNBC mark where Respondent attempted to
profit using Complainant’s
mark by redirecting Internet traffic to its own website).
There is no evidence on record, and
Respondent has not come forward with any proof that it is commonly known as
<buy-celebrex-prescriptions-online.com>.
Therefore, Respondent has failed to establish that it has rights or
legitimate interests in the disputed domain name pursuant to Policy
¶
4(c)(ii). See Gallup Inc. v. Amish Country Store, FA
96209 (Nat. Arb. Forum Jan. 23, 2001) (finding that Respondent does not have rights
in a domain name when Respondent is not known
by the mark); see also Compagnie de Saint Gobain v. Com-Union Corp.,
D2000-0020 (WIPO Mar. 14, 2000) (finding no rights or legitimate interest where
Respondent was not commonly known by the mark and
never applied for a license
or permission from Complainant to use the trademarked name).
The Panel finds that Policy ¶ 4(a)(ii)
has been satisfied.
Registration and Use in Bad Faith
Based on the fame of Complainant’s mark
and the fact that Respondent chose to register a domain name that would attract
Internet users
looking for Complainant’s products, it can be inferred that
Respondent had knowledge of Complainant’s rights when it registered the
disputed domain name. Registration of a
domain name that incorporates Complainant’s mark, despite knowledge of
Complainant’s rights, is evidence of bad
faith registration pursuant to Policy
¶ 4(a)(iii). See Entrepreneur Media,
Inc. v. Smith, [2002] USCA9 115; 279 F.3d 1135, 1148 (9th Cir. Feb. 11, 2002) (finding that
"[w]here an alleged infringer chooses a mark he knows to be similar to
another, one can
infer an intent to confuse"); see also Samsonite Corp. v. Colony Holding, FA
94313 (Nat. Arb. Forum Apr. 17, 2000) (finding that evidence of bad faith
includes actual or constructive knowledge of a commonly
known mark at the time
of registration).
Respondent used the disputed domain name
in order to attract Internet users interested in Complainant’s CELEBREX product
to its own
website. Respondent created
a likelihood of confusion for its own commercial gain, evidence of bad faith
pursuant to Policy ¶ 4(b)(iv). See State Fair of Texas v. Granbury.com, FA
95288 (Nat. Arb. Forum Sept. 12, 2000) (finding bad faith where Respondent
registered the domain name <bigtex.net> to infringe
on Complainant’s
goodwill and attract Internet users to Respondent’s website); see also Am. Online, Inc. v. Tencent Comm. Corp.,
FA 93668 (Nat. Arb. Forum Mar. 21, 2000) (finding bad faith where Respondent
registered and used an infringing domain name to attract
users to a website
sponsored by Respondent).
The Panel finds that Policy ¶ 4(a)(iii)
has been satisfied.
DECISION
Having established all three elements
required under the ICANN Policy, the Panel concludes that the requested relief
shall be hereby
granted.
Accordingly, it is Ordered that the
domain name <
buy-celebrex-prescriptions-online.com> be transferred from
Respondent to Complainant.
Tyrus R. Atkinson, Jr., Panelist
Dated: November 22, 2002
WorldLII:
Copyright Policy
|
Disclaimers
|
Privacy Policy
|
Feedback
URL: http://www.worldlii.org/int/other/GENDND/2002/1594.html